Cancers, Volume 14, Issue 22
2022 November-2 - 248 articles
Cover Story: COVID-19 vaccines are of high importance in patients with hematologic malignancies (HM), yet the efficacy of two-dose vaccination is often insufficient in such patients following ongoing cancer treatment and B-cell depletion. COVID-19 prime-boost vaccines aim to increase serologic response rates and overcome waning vaccine responses. To date, little is known about the efficacy of COVID-19 prime-boost vaccines in patients with HM as well as the differences between serological responders and non-responders. Moreover, the optimal management of low- or non-responders to COVID-19 booster vaccines in daily practice remains undefined. This study analyzed the efficacy of COVID-19 prime-boost vaccines in 200 patients with HM, identified negative predictive factors, and thus provides a risk-adapted guidance for the management of weak and failed responses to COVID-19 prime-boost vaccination. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.